header-19.jpg
Translational Research

Presentations 2018

In 2018, APCRC-Q researchers presented the following orals and posters at national and international conferences:

 The Brisbane Cancer Conference, Brisbane, 29-30 November 2018:

Invited speaker: A/Prof Elizabeth Williams, Preclinical models of prostate cancer

Invited speaker: Dr Handoo Rhee, Low dose testosterone for management of ADT toxicity

 

2nd Metabolism in Cancer and Stromal Cells, Leuven, Belgium, 26-27 November 2018:

          Poster: Sadowski M, Enhanced lipid uptake fuels the extensive transformation of the
          prostate cancer lipidome in response to androgen-targeted therapies

          Poster: Sadowski M, Targeting of serine biosynthesis and one-carbon metabolism in
          prostate cancer

          Poster: Sadowski M, PLA2G2A is a novel target to fight the development of therapy
          resistance in PCa cells

 

2nd Indo-Australian Symposium on Epithelial-Mesenchymal Transition, Pune, India, 24 October 2018:

          Invited speaker: Williams ED, Prostate cancer EMT and chemoresistance

          Invited speaker: Clements J, Cell plasticity and EMT of the kallikrein (KLK)-related
          peptidases in the tumour microenvironment

 

14th Indo-Australian Biotechnology Conference, Mumbai, India, 22-23 October 2018:

          Plenary speaker: Clements J, Proteases and the tumour microenvironment in the
          adaptive response to androgen targeted therapies in prostate cancer

          Invited speaker: Williams ED, Targeting prostate cancer bone metastasis

          Invited Speaker and Student Poster Judge: Hollier BG, Team-based research to
          combat the adaptive-resistance to androgen targeted therapies in advanced
          prostate cancer

 

Tissue Engineering and Regenerative Medicine International Society (TERMIS) World Congress, Kyoto, Japan, September 2018:

          Poster: Bock N, Developing a humanized bone model with high adipose content to
          study the effect of prostate cancer therapies on bone marrow adipocytes in vitro and
          in vivo

          Poster: Hutmacher DW, Bioengineering the human bone niche for advanced cancer
          – In vitro assessment of anti-androgen therapies in metastatic prostate cancer


American Association for Cancer Research Cancer Metabolism Conference, New York, September 2018:

          Poster talk: Philp L, Targeting Leptin Receptor signaling slows the progression of
          advanced prostate cancer

          Poster: Philp L, Targeting the adaptive response in Adiponectin Receptor signaling
          following androgen targeted therapy in prostate cancer: Efficacy in castrate LNCaP
          tumour xenografts in vivo

          Poster: Tousignant K, Enhanced lipid uptake fuels the extensive transformation of
          the prostate cancer lipidome in response to androgen-targeted therapies

 

The 2018 Asia-Pacific Prostate Cancer Conference, Brisbane, 22-24 August 2018:

Invited speaker:A/Prof Jyotsna Batra, A functional variation in PSA (KLK3) gene that confers lower risk is also associated with more aggressive disease and lower survival in men with Prostate Cancer.

Invited speaker: Ms Panchadsaram Janaththani, Functional analysis of GWAS identified 5p15 locus in Prostate Cancer

Invited speaker: Dr Saeid Alinezhad, In Vitro Culture and Therapeutic Profiling of Patient Derived Metastatic Prostate Cancer

Invited speaker: Dr Brett Hollier, Tumour plasticity as a therapeutic target in advanced Prostate Cancer

Invited speaker: Dr Jennifer Gunter, Targeting Prostate Cancer cell metabolism with biguanides

Invited speaker: Ms Michelle Maugham, NTSR1 promotes aggressive Prostate Cancer growth in metabolic syndrome

Invited speaker: Dr Martin Sadowski, The fat side of Enzalutamide

Invited speaker: Ms Lisa Philp, Targeting Leptin Receptor Signalling Slows the Progression of Advanced Prostate Cancer

Invited speaker: Dr Ati Taherian Fard, Systems biology exploration of the temporal dynamics of plasticity

Poster: Philp LK, Rockstroh A, Tevz G, Taherian Fard A, Gunter JH, Wade J, Sadowski MC, Otvos Jr L, Nelson CC. Targeting Leptin Receptor Signalling Slows the Progression of Advanced Prostate Cancer

Poster: Gunter JH, Philp L, Rhee H, Lee W, Hollier B, Lehman M, Sadowski MC, Nelson C. Comparing adaptive prostate cancer cell metabolism following anti-androgen and biguanide treatment

Poster: Sweeney K, Taherian Fard A, Upadhyaya A, Stylianou N, Tevz G, Rockstroh A, Fazil L, McPherson S, Pirlo K, Ratther E, Lehman M, Wang Y, Gleave M, Nelson CC,  Hollier BG. The role of ZEB1 in the adaptive response to ATT-mediated development of neuroendocrine prostate cancer.

Poster: Tousignant K, Talebi A, Rockstroh A, Atefeh Fard A, Poad B, Gupta R, Gunter J, Swinnen J, Blanksby S, Nelson C and Sadowski M. Enhanced lipid uptake and lipid remodelling are adaptive responses to androgen-targeted therapies in prostate cancer.

Poster: Ratther E, Sweeney K, Hu Q, Rockstroh A, Lehman M, Wang C, Bartonicek N, Stylianou N, Tvez G, Nelson CC, Williams ED and Hollier BG. Investigating androgen deprivation and enzalutamide-mediated epithelial plasticity in prostate cancer progression.

Poster: Yeh MC, Tse BWC, Fletcher NL, Zachary H Huston, Chelsea Stewart, Kamil Sokolowski, Varinder Jeet, Sandra Wissmueller, Thurecht KJ, Campbell DH, Walsh BJ, Nelson CC, Russell PJ. Targeted beta therapy of human prostate cancer in vivo with Lu- labelled MIL- antibody against glypican- (GPC-).

Poster: Jeet V, Rockstroh A, Yeh MC, Campbell DH, Walsh BJ, Russell PJ, Nelson CC. A Biomarker and a Therapeutic Target: Investigating the Role of Glypican- in Prostate Cancer.

Poster: Philp LK, Rockstroh A, Lehman M, Otvos Jr L, Wade J, Nelson CC. Targeting the Adaptive Response in Adiponectin Receptor Signalling Following Androgen Targeted Therapy in Prostate Cancer: Efficacy in Castrate LNCaP Tumour Xenografts In vivo.

Poster: Stylianou N, Lehman ML, Wang C, Jovanovic L, Rockstroh A, Taherian Fard A, Kashyap A, Fazli L, Buttyan R, Gleave M, Westbrook TF, Williams ED, Gunter JH , Nelson CC, Hollier BG. Revealing the transcriptional landscape of epithelial-mesenchymal plasticity in mCRPC.

Poster: Hu Q, Ratther E, Williams ED, Sweeney K, Nelson CC, Russell PJ, Hollier BG. Alterations of tumor vasculature and oxygen level of prostate cancer xenografts in vivo assessed by ultrasound and photoacoustic imaging.

Poster: Chandra S, Srinivasan S, Clements J, Batra J. Elucidating the role of Hepatocyte Nuclear Factor  Beta (HNFB) transcript variants in prostate cancer.

Poster: Farashi S, O’Mara GT, Kryza T, Clements J, Batra J. Causal variants that underlie miR-eQTLs in Prostate Cancer.

Poster: Subramaniam S, Jeet V, Walpole C, Nelson CC, Gunter JH, Clements JA, Batra J. Allele specific regulation of PDK by miRNAs in prostate cancer.

Poster: Matin F, Jeet V, Moya L, Selth LA, Chambers S, Australian Prostate Cancer BioResource, Clements JA, Batra J. A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer.

Poster: Srinivasan S, Buckle A, The Australian Prostate Cancer BioResource, Clements J, Batra J.      Functional analysis implicate a glycosylating prostate-cancer risk associated germline variant.

Poster: Batra J, Srinivasan S, Kryza T, Bock N, Stephens C, Dong Y, Panchadsaram J, Moya L, Röhl J, Perry-Keene JL, Buzacott K, Dadaev T, Brook MN, Lilja H, Spurdle A, Koistinen H, Stenman U, Kote-Jarai Z, Eeles R, The Practical Consortium, The Australian Prostate Cancer BioResource, Clements J. A functional variation in PSA (KLK) gene that confers lower risk is also associated with more aggressive disease and lower survival in men with prostate cancer.

Poster: Maharaj M, Herington A, Stephenson SA. Expanding the SUMO gene stable with the identification of SUMO.

Poster: Joshi A, Rhee H, Pryor D, Lehman M, McKenzie I, Munns J, Malone G, Chung E, Heathcote P, Preston J, Lawson M, Wood S, Gustafson S,  Miles K, Vela I. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities - results of a multi-centre, prospective clinical trial.

Poster: Panchadsaram J, Tevz G, Rockstroh A, Taherian Fard A, Lehman M, Nelson C,The Australian Prostate Cancer BioResource, Clements J, Batra J. Functional analysis of GWAS identified p locus in prostate cancer.

Poster: Mehawed G, Choi W, Joshi A, Rhee H, Gustafson S, Miles K, Vela I. Initial Experience of Novel Hybrid PSMA PET / MRI imaging for lymph node staging in prostate cancer. In vitro culture and therapeutic profiling of patient derived metastatic prostate cancer. 

 

Annual Meeting of the Endocrine Society of Australia, Adelaide, 19-22 August 2018:

          Poster: Maugham M, The Rag1-/- mouse: establishing links between obesity and
          prostate cancer

          Poster: Shah ET, A role for the long non-coding RNA GHRLOS in cancer. Novartis
          Junior Investigator Award Finalist

 

Poster: Williams ED, A bioengineered human construct that models osteoblastic prostate cancer metastasis, 17th Biennial Congress of the Metastasis Research Society, Houston, Texas, USA, 1-5 August 2018.

Invited speaker: Clements J, KLK peptidases in the tumor microenvironment: potential therapeutic targets in prostate and ovarian cancer, Pharmacology Department, Wayne State University School of Medicine, Detroit, USA, August 2018

Oral: Philp L, Targeting Leptin Receptor Signalling Slows the Progression of Advanced Prostate Cancer, TRI Symposium, Brisbane, 26 July 2018

Invited speaker: Sadowski M, Central Analytical Research Facility, QUT, Brisbane, July 2018

Invited speaker: Clements J, KLK peptidases as mediators of invasive processes in prostate and ovarian cancer, Gordon Research Conference “Protein Processing, Trafficking and Secretion”, Colby Sawyer College, New London, USA, July 2018